An Open Label Multi-Center Prospective Observational Study of Paliperidone Extended Release to Assess the Medication Satisfaction and Treatment Response in Patients with Schizophrenia.
- Author:
Bong Ju LEE
1
;
Donghwan SHIN
;
Mankil SEO
;
Yohan LEE
;
Dongseok YANG
;
Jinwoo PAC
;
Juyeon LEE
;
Won Myong BAHK
;
Tae Youn JUN
;
Sangkyu LEE
;
Byungjin CHAE
;
Kyungsik KIM
;
Eunjung JEONG
;
Seokyoung DO
;
Yong Lee JANG
;
Jongil LEE
;
Jaeyeol JEONG
;
Sanghoon KIM
;
Bo Hyun YOON
;
Shingyeom KIM
;
Moonsoo LEE
;
Jaewoo ROH
;
Minsook GIM
;
Sung Ku CHOI
;
Young Hoon KIM
Author Information
1. Department of Psychiatry, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Korea. npkyh@chol.com
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Paliperidone ER;
Schizophrenia;
Medication satisfaction questionnaire
- MeSH:
Humans;
Isoxazoles;
Prospective Studies;
Pyrimidines;
Surveys and Questionnaires;
Schizophrenia;
Sleep Stages;
Weights and Measures
- From:Korean Journal of Psychopharmacology
2012;23(3):88-96
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The aim of this study was to demonstrate changes of subjective medication satisfaction and clinical benefit after once-daily paliperidone extended release (ER) in treatment of schizophrenia. METHODS: In an open-label, observational, and multicenter study, 374 patients with schizophrenia who switched to paliperidone ER due to any reason were recruited. Medication Satisfaction Questionnaire (MSQ), Clinical Global Impression-Severity (CGI-S), Clinical Global Impression-Improvement and visual analogue scale for sleep (VAS) were assessed at baseline, 4 weeks and 8 weeks after treatment. We also examined the type, frequency, and severity of adverse events newly formed. RESULTS: Among 374 patients, 320 patients (76.5%) were included in the intent-to-treat analysis set. The mean dose of paliperidone ER was 5.33+/-2.31 mg/day at the initiation. At the endpoint, the mean dose of paliperidone ER was 6.68+/-3.13 mg/day. The percentages of patients satisfied with medication were changed from 40.9% at baseline to 67.8% at endpoint (p<0.001). Both CGI-S scores and VAS for daytime drowsiness were significantly decreased after 8 weeks (both p<0.0001) and mean scores of MSQ and VAS for sleep quality were improved after 8 weeks (both p<0.0001). CONCLUSION: After switching to paliperidone ER, 67.8% of patients with schizophrenia who had any reason to switch medication showed subjective satisfaction for medication and clinical improvement without significant adverse events. Regarding that medication satisfaction was associated with changes of clinical states, medication satisfaction can be used for measures for clinical scales in the treatment of schizophrenia.
